pharmaceutical investing Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
pharmaceutical investing Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
pharmaceutical investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
pharmaceutical investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
pharmaceutical investing Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
Blue Lagoon Secures $2 Million Line of Credit from Nicola Mining Enhancing Financial Flexibility Ahead of Production
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements
